Key result
Aliskiren showed no clinically relevant pharmacokinetic interactions when co-administered with allopurinol, celecoxib or cimetidine in healthy subjects.
Why the study?
Does co-administration of aliskiren with allopurinol, celecoxib, or cimetidine alter their pharmacokinetic profiles in healthy subjects?
Population
64 healthy subjects across three studies (n=20 for allopurinol, n=22 for celecoxib, n=22 for cimetidine)
Comparison
Aliskiren 300 mg once daily co-administered with… vs Aliskiren alone, allopurinol alone, or celecoxib…
Design
Other, open-label
Authors
Loading...
Supports co-administration without dose adjustment in healthy subjects; leaves open interactions in comorbid or polypharmacy patients.
Does co-administration of aliskiren with allopurinol, celecoxib, or cimetidine alter their pharmacokinetic profiles in healthy subjects?
Aliskiren can be co-administered with allopurinol, celecoxib, and cimetidine without clinically relevant pharmacokinetic interactions.
Ayalasomayajula et al. (2008) studied Healthy subjects (n=64). Aliskiren co-administered with allopurinol, celecoxib, or cimetidine vs. Aliskiren alone, allopurinol alone, or celecoxib alone was evaluated on Pharmacokinetic interactions (AUC and Cmax). Aliskiren showed no clinically relevant pharmacokinetic interactions when co-administered with allopurinol, celecoxib or cimetidine in healthy subjects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: